MovDisordV3, PascalFrancis, Corpus, bibRecord, 002840

Secondary nonresponsiveness to botulinum toxin type A in patients with oromandibular dystonia

Identifieur interne : 002840 ( PascalFrancis/Corpus ); précédent : 002839; suivant : 002841

Secondary nonresponsiveness to botulinum toxin type A in patients with oromandibular dystonia

Auteurs : Charles H. Adler ; Stewart A. Factor ; Mitchell Brin ; Kapil D. Sethi

Source :

Movement disorders [ 0885-3185 ] ; 2002.

RBID : Pascal:02-0204564

Descripteurs français

Pascal (Inist)
- Dystonie, Mandibule, Toxine, Botulisme, Bontoxilysin, Chimiothérapie, Myorelaxant, Voie intramusculaire, Inefficacité, Evolution, Traitement, Pronostic, Etude cas, Adulte, Mâle, Femelle.

English descriptors

KwdEn :
- Adult, Bontoxilysin, Botulism, Case study, Chemotherapy, Dystonia, Evolution, Female, Inefficiency, Intramuscular administration, Male, Mandible, Muscle relaxant, Prognosis, Toxin, Treatment.

Abstract

Intramuscular injection of botulinum toxin type A is the treatment of choice for most cases of oromandibular dystonia. We report on five patients with oromandibular dystonia that developed secondary nonresponsiveness to botulinum toxin type A following multiple injections over a 6-year period.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 17`
A06				`@2 1`
A08	`01`	`1`	`ENG`	`@1 Secondary nonresponsiveness to botulinum toxin type A in patients with oromandibular dystonia`
A11	`01`	`1`		`@1 ADLER (Charles H.)`
A11	`02`	`1`		`@1 FACTOR (Stewart A.)`
A11	`03`	`1`		`@1 BRIN (Mitchell)`
A11	`04`	`1`		`@1 SETHI (Kapil D.)`
A14	`01`			`@1 Parkinson's Disease and Movement Disorders Center, Mayo Clinic Scottsdale @2 Scottsdale, Arizona @3 USA @Z 1 aut.`
A14	`02`			`@1 Parkinson's Disease and Movement Disorders Center, Albany Medical College @2 Albany, New York @3 USA @Z 2 aut.`
A14	`03`			`@1 Movement Disorders Center, Mount Sinai Medical Center @2 New York, New York @3 USA @Z 3 aut.`
A14	`04`			`@1 Department of Neurology, Medical College of Georgia @2 Augusta, Georgia @3 USA @Z 4 aut.`
A20				`@1 158-161`
A21				`@1 2002`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000100147290250`
A44				`@0 0000 @1 © 2002 INIST-CNRS. All rights reserved.`
A45				`@0 13 ref.`
A47	`01`	`1`		`@0 02-0204564`
A60				`@1 P @3 CC`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	`@0 Intramuscular injection of botulinum toxin type A is the treatment of choice for most cases of oromandibular dystonia. We report on five patients with oromandibular dystonia that developed secondary nonresponsiveness to botulinum toxin type A following multiple injections over a 6-year period.`
C02	`01`	`X`		`@0 002B02C`
C03	`01`	`X`	`FRE`	`@0 Dystonie @5 01`
C03	`01`	`X`	`ENG`	`@0 Dystonia @5 01`
C03	`01`	`X`	`SPA`	`@0 Distonía @5 01`
C03	`02`	`X`	`FRE`	`@0 Mandibule @5 02`
C03	`02`	`X`	`ENG`	`@0 Mandible @5 02`
C03	`02`	`X`	`SPA`	`@0 Mandíbula @5 02`
C03	`03`	`X`	`FRE`	`@0 Toxine @5 04`
C03	`03`	`X`	`ENG`	`@0 Toxin @5 04`
C03	`03`	`X`	`SPA`	`@0 Toxina @5 04`
C03	`04`	`X`	`FRE`	`@0 Botulisme @5 05`
C03	`04`	`X`	`ENG`	`@0 Botulism @5 05`
C03	`04`	`X`	`SPA`	`@0 Botulismo @5 05`
C03	`05`	`X`	`FRE`	`@0 Bontoxilysin @2 FE @2 FR @5 06`
C03	`05`	`X`	`ENG`	`@0 Bontoxilysin @2 FE @2 FR @5 06`
C03	`05`	`X`	`SPA`	`@0 Bontoxilysin @2 FE @2 FR @5 06`
C03	`06`	`X`	`FRE`	`@0 Chimiothérapie @5 07`
C03	`06`	`X`	`ENG`	`@0 Chemotherapy @5 07`
C03	`06`	`X`	`SPA`	`@0 Quimioterapia @5 07`
C03	`07`	`X`	`FRE`	`@0 Myorelaxant @5 08`
C03	`07`	`X`	`ENG`	`@0 Muscle relaxant @5 08`
C03	`07`	`X`	`SPA`	`@0 Relajante muscular @5 08`
C03	`08`	`X`	`FRE`	`@0 Voie intramusculaire @5 09`
C03	`08`	`X`	`ENG`	`@0 Intramuscular administration @5 09`
C03	`08`	`X`	`SPA`	`@0 Vía intramuscular @5 09`
C03	`09`	`X`	`FRE`	`@0 Inefficacité @5 10`
C03	`09`	`X`	`ENG`	`@0 Inefficiency @5 10`
C03	`09`	`X`	`SPA`	`@0 Ineficacia @5 10`
C03	`10`	`X`	`FRE`	`@0 Evolution @5 16`
C03	`10`	`X`	`ENG`	`@0 Evolution @5 16`
C03	`10`	`X`	`SPA`	`@0 Evolución @5 16`
C03	`11`	`X`	`FRE`	`@0 Traitement @5 17`
C03	`11`	`X`	`ENG`	`@0 Treatment @5 17`
C03	`11`	`X`	`SPA`	`@0 Tratamiento @5 17`
C03	`12`	`X`	`FRE`	`@0 Pronostic @5 18`
C03	`12`	`X`	`ENG`	`@0 Prognosis @5 18`
C03	`12`	`X`	`SPA`	`@0 Pronóstico @5 18`
C03	`13`	`X`	`FRE`	`@0 Etude cas @5 19`
C03	`13`	`X`	`ENG`	`@0 Case study @5 19`
C03	`13`	`X`	`SPA`	`@0 Estudio caso @5 19`
C03	`14`	`X`	`FRE`	`@0 Adulte @5 20`
C03	`14`	`X`	`ENG`	`@0 Adult @5 20`
C03	`14`	`X`	`SPA`	`@0 Adulto @5 20`
C03	`15`	`X`	`FRE`	`@0 Mâle @5 21`
C03	`15`	`X`	`ENG`	`@0 Male @5 21`
C03	`15`	`X`	`SPA`	`@0 Macho @5 21`
C03	`16`	`X`	`FRE`	`@0 Femelle @5 22`
C03	`16`	`X`	`ENG`	`@0 Female @5 22`
C03	`16`	`X`	`SPA`	`@0 Hembra @5 22`
C07	`01`	`X`	`FRE`	`@0 Bactériose`
C07	`01`	`X`	`ENG`	`@0 Bacteriosis`
C07	`01`	`X`	`SPA`	`@0 Bacteriosis`
C07	`02`	`X`	`FRE`	`@0 Infection`
C07	`02`	`X`	`ENG`	`@0 Infection`
C07	`02`	`X`	`SPA`	`@0 Infección`
C07	`03`	`X`	`FRE`	`@0 Metalloendopeptidases @2 FE`
C07	`03`	`X`	`ENG`	`@0 Metalloendopeptidases @2 FE`
C07	`03`	`X`	`SPA`	`@0 Metalloendopeptidases @2 FE`
C07	`04`	`X`	`FRE`	`@0 Peptidases @2 FE`
C07	`04`	`X`	`ENG`	`@0 Peptidases @2 FE`
C07	`04`	`X`	`SPA`	`@0 Peptidases @2 FE`
C07	`05`	`X`	`FRE`	`@0 Hydrolases @2 FE`
C07	`05`	`X`	`ENG`	`@0 Hydrolases @2 FE`
C07	`05`	`X`	`SPA`	`@0 Hydrolases @2 FE`
C07	`06`	`X`	`FRE`	`@0 Enzyme`
C07	`06`	`X`	`ENG`	`@0 Enzyme`
C07	`06`	`X`	`SPA`	`@0 Enzima`
C07	`07`	`X`	`FRE`	`@0 Homme`
C07	`07`	`X`	`ENG`	`@0 Human`
C07	`07`	`X`	`SPA`	`@0 Hombre`
C07	`08`	`X`	`FRE`	`@0 Muscle strié pathologie @5 37`
C07	`08`	`X`	`ENG`	`@0 Striated muscle disease @5 37`
C07	`08`	`X`	`SPA`	`@0 Músculo estriado patología @5 37`
C07	`09`	`X`	`FRE`	`@0 Système nerveux pathologie @5 38`
C07	`09`	`X`	`ENG`	`@0 Nervous system diseases @5 38`
C07	`09`	`X`	`SPA`	`@0 Sistema nervioso patología @5 38`
C07	`10`	`X`	`FRE`	`@0 Trouble neurologique @5 39`
C07	`10`	`X`	`ENG`	`@0 Neurological disorder @5 39`
C07	`10`	`X`	`SPA`	`@0 Trastorno neurológico @5 39`
C07	`11`	`X`	`FRE`	`@0 Mouvement involontaire @5 40`
C07	`11`	`X`	`ENG`	`@0 Involuntary movement @5 40`
C07	`11`	`X`	`SPA`	`@0 Movimiento involuntario @5 40`
C07	`12`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 41`
C07	`12`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 41`
C07	`12`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 41`
N21				`@1 119`
N82				`@1 PSI`

Format Inist (serveur)

NO :	PASCAL 02-0204564 INIST
ET :	Secondary nonresponsiveness to botulinum toxin type A in patients with oromandibular dystonia
AU :	ADLER (Charles H.); FACTOR (Stewart A.); BRIN (Mitchell); SETHI (Kapil D.)
AF :	Parkinson's Disease and Movement Disorders Center, Mayo Clinic Scottsdale/Scottsdale, Arizona/Etats-Unis (1 aut.); Parkinson's Disease and Movement Disorders Center, Albany Medical College/Albany, New York/Etats-Unis (2 aut.); Movement Disorders Center, Mount Sinai Medical Center/New York, New York/Etats-Unis (3 aut.); Department of Neurology, Medical College of Georgia/Augusta, Georgia/Etats-Unis (4 aut.)
DT :	Publication en série; Courte communication, note brève; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2002; Vol. 17; No. 1; Pp. 158-161; Bibl. 13 ref.
LA :	Anglais
EA :	Intramuscular injection of botulinum toxin type A is the treatment of choice for most cases of oromandibular dystonia. We report on five patients with oromandibular dystonia that developed secondary nonresponsiveness to botulinum toxin type A following multiple injections over a 6-year period.
CC :	002B02C
FD :	Dystonie; Mandibule; Toxine; Botulisme; Bontoxilysin; Chimiothérapie; Myorelaxant; Voie intramusculaire; Inefficacité; Evolution; Traitement; Pronostic; Etude cas; Adulte; Mâle; Femelle
FG :	Bactériose; Infection; Metalloendopeptidases; Peptidases; Hydrolases; Enzyme; Homme; Muscle strié pathologie; Système nerveux pathologie; Trouble neurologique; Mouvement involontaire; Extrapyramidal syndrome
ED :	Dystonia; Mandible; Toxin; Botulism; Bontoxilysin; Chemotherapy; Muscle relaxant; Intramuscular administration; Inefficiency; Evolution; Treatment; Prognosis; Case study; Adult; Male; Female
EG :	Bacteriosis; Infection; Metalloendopeptidases; Peptidases; Hydrolases; Enzyme; Human; Striated muscle disease; Nervous system diseases; Neurological disorder; Involuntary movement; Extrapyramidal syndrome
SD :	Distonía; Mandíbula; Toxina; Botulismo; Bontoxilysin; Quimioterapia; Relajante muscular; Vía intramuscular; Ineficacia; Evolución; Tratamiento; Pronóstico; Estudio caso; Adulto; Macho; Hembra
LO :	INIST-20953.354000100147290250
ID :	02-0204564

Links to Exploration step

Pascal:02-0204564

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Secondary nonresponsiveness to botulinum toxin type A in patients with oromandibular dystonia</title>
<author><name sortKey="Adler, Charles H" sort="Adler, Charles H" uniqKey="Adler C" first="Charles H." last="Adler">Charles H. Adler</name>
<affiliation><inist:fA14 i1="01"><s1>Parkinson's Disease and Movement Disorders Center, Mayo Clinic Scottsdale</s1>
<s2>Scottsdale, Arizona</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Factor, Stewart A" sort="Factor, Stewart A" uniqKey="Factor S" first="Stewart A." last="Factor">Stewart A. Factor</name>
<affiliation><inist:fA14 i1="02"><s1>Parkinson's Disease and Movement Disorders Center, Albany Medical College</s1>
<s2>Albany, New York</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Brin, Mitchell" sort="Brin, Mitchell" uniqKey="Brin M" first="Mitchell" last="Brin">Mitchell Brin</name>
<affiliation><inist:fA14 i1="03"><s1>Movement Disorders Center, Mount Sinai Medical Center</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sethi, Kapil D" sort="Sethi, Kapil D" uniqKey="Sethi K" first="Kapil D." last="Sethi">Kapil D. Sethi</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Neurology, Medical College of Georgia</s1>
<s2>Augusta, Georgia</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">02-0204564</idno>
<date when="2002">2002</date>
<idno type="stanalyst">PASCAL 02-0204564 INIST</idno>
<idno type="RBID">Pascal:02-0204564</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002840</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Secondary nonresponsiveness to botulinum toxin type A in patients with oromandibular dystonia</title>
<author><name sortKey="Adler, Charles H" sort="Adler, Charles H" uniqKey="Adler C" first="Charles H." last="Adler">Charles H. Adler</name>
<affiliation><inist:fA14 i1="01"><s1>Parkinson's Disease and Movement Disorders Center, Mayo Clinic Scottsdale</s1>
<s2>Scottsdale, Arizona</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Factor, Stewart A" sort="Factor, Stewart A" uniqKey="Factor S" first="Stewart A." last="Factor">Stewart A. Factor</name>
<affiliation><inist:fA14 i1="02"><s1>Parkinson's Disease and Movement Disorders Center, Albany Medical College</s1>
<s2>Albany, New York</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Brin, Mitchell" sort="Brin, Mitchell" uniqKey="Brin M" first="Mitchell" last="Brin">Mitchell Brin</name>
<affiliation><inist:fA14 i1="03"><s1>Movement Disorders Center, Mount Sinai Medical Center</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sethi, Kapil D" sort="Sethi, Kapil D" uniqKey="Sethi K" first="Kapil D." last="Sethi">Kapil D. Sethi</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Neurology, Medical College of Georgia</s1>
<s2>Augusta, Georgia</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2002">2002</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Bontoxilysin</term>
<term>Botulism</term>
<term>Case study</term>
<term>Chemotherapy</term>
<term>Dystonia</term>
<term>Evolution</term>
<term>Female</term>
<term>Inefficiency</term>
<term>Intramuscular administration</term>
<term>Male</term>
<term>Mandible</term>
<term>Muscle relaxant</term>
<term>Prognosis</term>
<term>Toxin</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Dystonie</term>
<term>Mandibule</term>
<term>Toxine</term>
<term>Botulisme</term>
<term>Bontoxilysin</term>
<term>Chimiothérapie</term>
<term>Myorelaxant</term>
<term>Voie intramusculaire</term>
<term>Inefficacité</term>
<term>Evolution</term>
<term>Traitement</term>
<term>Pronostic</term>
<term>Etude cas</term>
<term>Adulte</term>
<term>Mâle</term>
<term>Femelle</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Intramuscular injection of botulinum toxin type A is the treatment of choice for most cases of oromandibular dystonia. We report on five patients with oromandibular dystonia that developed secondary nonresponsiveness to botulinum toxin type A following multiple injections over a 6-year period.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>17</s2>
</fA05>
<fA06><s2>1</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Secondary nonresponsiveness to botulinum toxin type A in patients with oromandibular dystonia</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>ADLER (Charles H.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>FACTOR (Stewart A.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>BRIN (Mitchell)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>SETHI (Kapil D.)</s1>
</fA11>
<fA14 i1="01"><s1>Parkinson's Disease and Movement Disorders Center, Mayo Clinic Scottsdale</s1>
<s2>Scottsdale, Arizona</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Parkinson's Disease and Movement Disorders Center, Albany Medical College</s1>
<s2>Albany, New York</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Movement Disorders Center, Mount Sinai Medical Center</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Neurology, Medical College of Georgia</s1>
<s2>Augusta, Georgia</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA20><s1>158-161</s1>
</fA20>
<fA21><s1>2002</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000100147290250</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2002 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>13 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>02-0204564</s0>
</fA47>
<fA60><s1>P</s1>
<s3>CC</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Intramuscular injection of botulinum toxin type A is the treatment of choice for most cases of oromandibular dystonia. We report on five patients with oromandibular dystonia that developed secondary nonresponsiveness to botulinum toxin type A following multiple injections over a 6-year period.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02C</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Dystonie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Dystonia</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Distonía</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Mandibule</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Mandible</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Mandíbula</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Toxine</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Toxin</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Toxina</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Botulisme</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Botulism</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Botulismo</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Bontoxilysin</s0>
<s2>FE</s2>
<s2>FR</s2>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Bontoxilysin</s0>
<s2>FE</s2>
<s2>FR</s2>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Bontoxilysin</s0>
<s2>FE</s2>
<s2>FR</s2>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Myorelaxant</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Muscle relaxant</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Relajante muscular</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Voie intramusculaire</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Intramuscular administration</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Vía intramuscular</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Inefficacité</s0>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Inefficiency</s0>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Ineficacia</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Evolution</s0>
<s5>16</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Evolution</s0>
<s5>16</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Evolución</s0>
<s5>16</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Traitement</s0>
<s5>17</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Treatment</s0>
<s5>17</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>17</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Pronostic</s0>
<s5>18</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Prognosis</s0>
<s5>18</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Pronóstico</s0>
<s5>18</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Etude cas</s0>
<s5>19</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Case study</s0>
<s5>19</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Estudio caso</s0>
<s5>19</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Adulte</s0>
<s5>20</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Adult</s0>
<s5>20</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Adulto</s0>
<s5>20</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Mâle</s0>
<s5>21</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Male</s0>
<s5>21</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA"><s0>Macho</s0>
<s5>21</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE"><s0>Femelle</s0>
<s5>22</s5>
</fC03>
<fC03 i1="16" i2="X" l="ENG"><s0>Female</s0>
<s5>22</s5>
</fC03>
<fC03 i1="16" i2="X" l="SPA"><s0>Hembra</s0>
<s5>22</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Bactériose</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Bacteriosis</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Bacteriosis</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Infection</s0>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Infection</s0>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Infección</s0>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Metalloendopeptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Metalloendopeptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Metalloendopeptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Peptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Peptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Peptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Enzyme</s0>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Enzyme</s0>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Enzima</s0>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Homme</s0>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Human</s0>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Hombre</s0>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Muscle strié pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Striated muscle disease</s0>
<s5>37</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Músculo estriado patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>38</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="10" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>39</s5>
</fC07>
<fC07 i1="10" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="10" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>39</s5>
</fC07>
<fC07 i1="11" i2="X" l="FRE"><s0>Mouvement involontaire</s0>
<s5>40</s5>
</fC07>
<fC07 i1="11" i2="X" l="ENG"><s0>Involuntary movement</s0>
<s5>40</s5>
</fC07>
<fC07 i1="11" i2="X" l="SPA"><s0>Movimiento involuntario</s0>
<s5>40</s5>
</fC07>
<fC07 i1="12" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>41</s5>
</fC07>
<fC07 i1="12" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>41</s5>
</fC07>
<fC07 i1="12" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>41</s5>
</fC07>
<fN21><s1>119</s1>
</fN21>
<fN82><s1>PSI</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 02-0204564 INIST</NO>
<ET>Secondary nonresponsiveness to botulinum toxin type A in patients with oromandibular dystonia</ET>
<AU>ADLER (Charles H.); FACTOR (Stewart A.); BRIN (Mitchell); SETHI (Kapil D.)</AU>
<AF>Parkinson's Disease and Movement Disorders Center, Mayo Clinic Scottsdale/Scottsdale, Arizona/Etats-Unis (1 aut.); Parkinson's Disease and Movement Disorders Center, Albany Medical College/Albany, New York/Etats-Unis (2 aut.); Movement Disorders Center, Mount Sinai Medical Center/New York, New York/Etats-Unis (3 aut.); Department of Neurology, Medical College of Georgia/Augusta, Georgia/Etats-Unis (4 aut.)</AF>
<DT>Publication en série; Courte communication, note brève; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2002; Vol. 17; No. 1; Pp. 158-161; Bibl. 13 ref.</SO>
<LA>Anglais</LA>
<EA>Intramuscular injection of botulinum toxin type A is the treatment of choice for most cases of oromandibular dystonia. We report on five patients with oromandibular dystonia that developed secondary nonresponsiveness to botulinum toxin type A following multiple injections over a 6-year period.</EA>
<CC>002B02C</CC>
<FD>Dystonie; Mandibule; Toxine; Botulisme; Bontoxilysin; Chimiothérapie; Myorelaxant; Voie intramusculaire; Inefficacité; Evolution; Traitement; Pronostic; Etude cas; Adulte; Mâle; Femelle</FD>
<FG>Bactériose; Infection; Metalloendopeptidases; Peptidases; Hydrolases; Enzyme; Homme; Muscle strié pathologie; Système nerveux pathologie; Trouble neurologique; Mouvement involontaire; Extrapyramidal syndrome</FG>
<ED>Dystonia; Mandible; Toxin; Botulism; Bontoxilysin; Chemotherapy; Muscle relaxant; Intramuscular administration; Inefficiency; Evolution; Treatment; Prognosis; Case study; Adult; Male; Female</ED>
<EG>Bacteriosis; Infection; Metalloendopeptidases; Peptidases; Hydrolases; Enzyme; Human; Striated muscle disease; Nervous system diseases; Neurological disorder; Involuntary movement; Extrapyramidal syndrome</EG>
<SD>Distonía; Mandíbula; Toxina; Botulismo; Bontoxilysin; Quimioterapia; Relajante muscular; Vía intramuscular; Ineficacia; Evolución; Tratamiento; Pronóstico; Estudio caso; Adulto; Macho; Hembra</SD>
<LO>INIST-20953.354000100147290250</LO>
<ID>02-0204564</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002840 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 002840 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:02-0204564
   |texte=   Secondary nonresponsiveness to botulinum toxin type A in patients with oromandibular dystonia
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Secondary nonresponsiveness to botulinum toxin type A in patients with oromandibular dystonia

Secondary nonresponsiveness to botulinum toxin type A in patients with oromandibular dystonia

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri